You have 9 free searches left this month | for more free features.

High Risk Myeloid Leukemia

Showing 1 - 25 of >10,000

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Acute Myeloid Leukemia, High-Risk and Very High-Risk MDS Trial (SGR-2921)

Not yet recruiting
  • Acute Myeloid Leukemia
  • High-Risk and Very High-Risk Myelodysplastic Syndromes
  • (no location specified)
Jul 25, 2023

Allogeneic Hematopoietic Stem Cell Transplantation, Acute Myeloid Leukemia, Myelodysplastic Syndrome Trial in Suzhou

Recruiting
  • Allogeneic Hematopoietic Stem Cell Transplantation
  • +2 more
  • VEN+AZA+Modified BUCY
  • Suzhou, Jiangsu, China
    The First Affiliated Hospital of Soochow University
Apr 10, 2023

Leukemia, Myeloid, Acute Trial in Chengdu (Chidamide)

Recruiting
  • Leukemia, Myeloid, Acute
  • Chengdu, Sichuan, China
    West China Hospital of Sichuan University
Dec 27, 2022

Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia Trial in Duarte (Decitabine,

Active, not recruiting
  • Acute Myeloid Leukemia
  • +5 more
  • Duarte, California
    City of Hope Medical Center
Jan 4, 2023

High Risk Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia Trial in Houston

Completed
  • High Risk Myelodysplastic Syndrome
  • +2 more
  • Daratumumab
  • Houston, Texas
    M D Anderson Cancer Center
Nov 21, 2022

Alkylating Agent-Related Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia Trial in Houston (Laboratory Biomarker

Completed
  • Alkylating Agent-Related Acute Myeloid Leukemia
  • Secondary Acute Myeloid Leukemia
  • Houston, Texas
    M D Anderson Cancer Center
Oct 18, 2022

Acute Myeloid Leukemia, MDS Trial (idarubicin, Cytarabine)

Not yet recruiting
  • Acute Myeloid Leukemia
  • Myelodysplastic Syndromes
  • (no location specified)
Sep 18, 2023

Acute Myeloid Leukemia, Blasts 20 Percent or More of Bone Marrow Nucleated Cells, High Risk Myelodysplastic Syndrome Trial in

Recruiting
  • Acute Myeloid Leukemia
  • +7 more
  • Houston, Texas
    M D Anderson Cancer Center
Dec 7, 2022

MDS, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic Trial in Newcastle (Subcutaneous azacitidine, Oral

Not yet recruiting
  • Myelodysplastic Syndromes
  • +3 more
  • Subcutaneous azacitidine
  • Oral decitabine/cedazuridine
  • Newcastle, New South Wales, Australia
    Calvary Mater Newcastle
May 29, 2023

Leukemia, Myeloid, Acute, MDS, Hematopoietic Stem Cell Transplantation Trial in Shanghai (Venetoclax plus RIC)

Not yet recruiting
  • Leukemia, Myeloid, Acute
  • +3 more
  • Venetoclax plus RIC
  • Shanghai, Shanghai, China
    Shanghai General Hospital
Oct 12, 2022

Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, High Risk

Recruiting
  • Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
  • +5 more
  • Gemtuzumab Ozogamicin
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
Sep 22, 2022

Acute Myeloid Leukemia, Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia Trial in Houston (Decitabine, Quizartinib,

Recruiting
  • Acute Myeloid Leukemia
  • +4 more
  • Houston, Texas
    M D Anderson Cancer Center
Jan 27, 2023

Acute Myeloid Leukemia (AML), High-risk Myelodysplastic Syndrome (MDS) Trial in Worldwide (HDM201, MBG453, Venetoclax)

Active, not recruiting
  • Acute Myeloid Leukemia (AML)
  • High-risk Myelodysplastic Syndrome (MDS)
  • Durham, North Carolina
  • +8 more
Dec 13, 2022

Acute Myeloid Leukemia, MDS Trial in Hangzhou (Decitabine for Injection, VENCLYXTO)

Not yet recruiting
  • Acute Myeloid Leukemia
  • Myelodysplastic Syndromes
  • Hangzhou, Zhejiang, China
    The First Affiliated Hospital, College of Medicine, Zhejiang Uni
Sep 18, 2023

Acute Myeloid Leukemia, Allogeneic Stem Cell Transplantation Trial (Siremadlin)

Recruiting
  • Acute Myeloid Leukemia
  • Allogeneic Stem Cell Transplantation
  • Tel Aviv, Israel
  • +2 more
Jan 23, 2023

Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia Trial (UAE Inhibitor TAK-243)

Not yet recruiting
  • Myelodysplastic Syndrome
  • +4 more
  • UAE Inhibitor TAK-243
  • (no location specified)
Oct 20, 2022

Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid

Active, not recruiting
  • Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
  • +9 more
  • Sewell, New Jersey
  • +4 more
Dec 13, 2022

Acute Myelogenous Leukemia Trial in Rochester (Decitabine)

Completed
  • Acute Myelogenous Leukemia
  • Rochester, New York
    University of Rochester
Jul 1, 2022

Leukemia, Myeloid, Acute Trial in Japan (Cusatuzumab, Azacitidine)

Completed
  • Leukemia, Myeloid, Acute
  • Fukushima, Japan
  • +4 more
Aug 8, 2022

Leukemia Trial in Houston (Cladribine, Cytarabine, Decitabine)

Recruiting
  • Leukemia
  • Houston, Texas
    University of Texas MD Anderson Cancer Center
Aug 23, 2022

Acute Myeloid Leukemia, MDS Trial (SPRX002, ARC-T)

Not yet recruiting
  • Acute Myeloid Leukemia
  • Myelodysplastic Syndromes
  • SPRX002
  • ARC-T
  • (no location specified)
Jul 12, 2022

Myeloid Malignancies, Acute Myeloid Leukemia, Myelodysplastic Syndrome Trial in Houston (Cyclophosphamide, Mesna, Filgrastim)

Recruiting
  • Myeloid Malignancies
  • +3 more
  • Houston, Texas
    M D Anderson Caner Center
Nov 17, 2022

Acute Myeloid Leukemia, Myelodysplastic Syndrome Trial in Duarte, New York, Houston (BTX-A51)

Recruiting
  • Acute Myeloid Leukemia
  • Myelodysplastic Syndrome
  • Duarte, California
  • +2 more
Sep 8, 2022

Acute Myeloid Leukemia, Adult, MDS Trial in Marseille, Paris, Pierre-BĂ©nite (ABD-3001)

Active, not recruiting
  • Acute Myeloid Leukemia, Adult
  • Myelodysplastic Syndromes
  • Marseille, France
  • +2 more
Jan 19, 2023

Acute Myeloid Leukemia, Myeloid Tumor Trial in Seattle (Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy)

Not yet recruiting
  • Acute Myeloid Leukemia
  • Myeloid Neoplasm
  • Biospecimen Collection
  • +9 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Sep 5, 2023